DRMA Valuation

Dermata Therapeutics Inc

Add to Watchlist

Advanced Chart

5.980

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

DRMA Relative Valuation

DRMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DRMA is overvalued; if below, it's undervalued.

Historical Valuation

Dermata Therapeutics Inc (DRMA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.69. The fair price of Dermata Therapeutics Inc (DRMA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.98

Fair

-0.49

Trailing

Forward

0.00

EV/EBITDA

Dermata Therapeutics Inc. (DRMA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.19

EV/EBIT

Dermata Therapeutics Inc. (DRMA) has a current EV/EBIT of 0.19. The 5-year average EV/EBIT is 0.07. The thresholds are as follows: Strongly Undervalued below -1.26, Undervalued between -1.26 and -0.59, Fairly Valued between 0.73 and -0.59, Overvalued between 0.73 and 1.39, and Strongly Overvalued above 1.39. The current Forward EV/EBIT of 0.19 falls within the Historic Trend Line -Fairly Valued range.

0.00

Dermata Therapeutics Inc. (DRMA) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Dermata Therapeutics Inc. (DRMA) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.25. The thresholds are as follows: Strongly Undervalued below -1.57, Undervalued between -1.57 and -0.91, Fairly Valued between 0.42 and -0.91, Overvalued between 0.42 and 1.08, and Strongly Overvalued above 1.08. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Dermata Therapeutics Inc. (DRMA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Dermata Therapeutics Inc (DRMA) has a current Price-to-Book (P/B) ratio of 0.68. Compared to its 3-year average P/B ratio of 0.55 , the current P/B ratio is approximately 22.94% higher. Relative to its 5-year average P/B ratio of 0.73, the current P/B ratio is about -6.32% higher. Dermata Therapeutics Inc (DRMA) has a Forward Free Cash Flow (FCF) yield of approximately -276.70%. Compared to its 3-year average FCF yield of -282.69%, the current FCF yield is approximately -2.12% lower. Relative to its 5-year average FCF yield of -226.08% , the current FCF yield is about 22.39% lower.

0.68

P/B

Median3y

0.55

Median5y

0.73

-276.70

FCF Yield

Median3y

-282.69

Median5y

-226.08

Competitors Valuation Multiple

The average P/S ratio for DRMA's competitors is 0.31, providing a benchmark for relative valuation. Dermata Therapeutics Inc Corp (DRMA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DRMA.O

Dermata Therapeutics Inc

XORTX Therapeutics Inc

Loss

4.28M

QNRX.O

Quoin Pharmaceuticals Ltd

Xenetic Biosciences Inc

1.64

-18.79%

4.41M

Performance Decomposition

Market capitalization of DRMA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of DRMA in the past 1 year is driven by Unknown.